Central Nervous System
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead…
Ipsen and Skyhawk partner to develop rare neurological therapies
Ipsen has entered an exclusive global collaboration with Skyhawk Therapeutics for the discovery and development of new small molecules that…
Essential Pharma acquires Reminyl from Janssen Pharmaceutica
Speciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl oral capsules from Johnson & Johnson company Janssen Pharmaceutica.…
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…
Norgine seeks approval for high-risk neuroblastoma treatment
Norgine has sought approval for eflornithine (difluoromethylornithine [DFMO]) for the treatment of patients with high-risk neuroblastoma (HRNB). The development marks…
Lonza links with NeuroSense to detect exosome-based biomarkers
Swiss contract manufacturer Lonza and NeuroSense Therapeutics have partnered to detect exosome-based biomarkers to bolster diagnostics and treatments for neurodegenerative…
Seaport emerges after $100m raise with ex-Karuna team at helm
Seaport Therapeutics has entered the neuropsychiatry treatment space after emerging with $100m from a financing round. ARCH Venture Partners and…
FDA gives nod to BrainStorm for ALS trial after Phase III flop
BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…
Acumen and Lonza to produce Alzheimer’s drug sabirnetug
Acumen Pharmaceuticals has entered a strategic partnership with Swiss contract manufacturer Lonza to further the development of sabirnetug (ACU193), a…
MiNA and Nippon Shinyaku enter RNAa therapeutics deal
MiNA Therapeutics has entered a research partnership and licensing agreement with Nippon Shinyaku to develop small activating RNA (RNAa) therapeutics…
